HPV vaccine

The Long Wait for India’s HPV Vaccine Rollout Ends, but Challenges Persist

On January 30, 2026, the Union Ministry of Health and Family Welfare set an ambitious target: vaccinate 6 crore girls aged 9–14 against the Human Papillomavirus (HPV) by the end of 2027. This announcement came amidst India’s decades-long struggle to stem cervical cancer, which claims over 77,000 women annually—a grim statistic that makes India home to almost a fifth of the world’s cervical cancer cases. The massive ₹3,000 crore allocation announced for this programme suggests political intent. The question, however, is whether intent can overcome the familiar structural bottlenecks of India’s public health ecosystem.

The government’s decision to indigenously produce the vaccine—thriving on the Serum Institute of India’s Cervavac—marks a pivot in reducing dependency on exorbitantly priced imports, which previously cost ₹2,100–₹3,500 per dose. The lower cost of Cervavac, approximately ₹200–₹400 per dose, is indeed a breakthrough for accessibility. But the tougher challenge lies not in production, but in targeted delivery, especially to tribal, rural, and urban-poor demographics where awareness and access remain abysmally low. The rollout may have started, but its success is far from assured.

Institutional Architecture: Legal and Fiscal Underpinnings

India’s National Technical Advisory Group on Immunization (NTAGI) had recommended the inclusion of the HPV vaccine in the Universal Immunization Programme (UIP) as early as 2016—a step that took nearly a decade to materialize. The project will operate under the aegis of UIP, which already vaccinates nearly 2.67 crore children annually. Immunizations will primarily take place through pre-existing platforms including government health centres, anganwadi outreach services, and school-based drives.

The programme draws on the constitutional mandate under Article 47, which places the improvement of public health squarely within the state's responsibility. Most of the funding for this ₹3,000 crore initiative will stem from a pooled tax revenue share allocated under the National Health Mission (NHM). However, the absence of a dedicated HPV-specific allocation line and interdependent public health funding mechanisms raise doubts about whether resources will be consistently disbursed without encroaching upon other critical healthcare priorities.

Ground Challenges: Awareness and Acceptance

For all its merit, the HPV vaccine arrives in a cultural milieu plagued by misinformation and stigma surrounding both cervical cancer and female reproductive health. A 2023 study from The Lancet Oncology revealed that only 2% of Indian parents surveyed were aware of HPV’s link to cervical cancer. The problem isn’t merely a lack of information—it is interwoven with entrenched taboos.

School-based immunization campaigns for girls, while logical in design, face resistance from parents due to perceived adverse side effects or unfounded assent that such vaccinations might encourage premarital sexual activity. India’s questionable messaging strategy during past campaigns, as seen in the polio and COVID-19 drives, exemplifies what happens when engagement with communities is superficial rather than substantive. Without sustained local-level advocacy, cultural resistance threatens to undermine the programme before its benefits reach scale.

Another layer of inequity lies in over-promised universalism. The Ministry has guaranteed that the vaccine will be administered free of cost to eligible adolescent girls in government schools and anganwadi centres. But what about the 25% of out-of-school girls, many from marginalised communities, who fall through the cracks? The ₹3,000 crore budget appears robust on paper, but without specific provisions for tracking and targeting the most vulnerable, the institutional arrangement cannot translate to equitable outcomes.

A Structural Tension: Centre-State Coordination

The Union government may fund and frame this rollout, but its execution ultimately relies on state governments, whose capacity for immunization delivery is uneven. Bihar and Uttar Pradesh, with some of the poorest immunization rates in the country, must shoulder a disproportionately larger portion of the implementation burden. Their inadequate healthcare worker-to-population ratios and patchy supply chain networks concern not just HPV interventions but inoculation in general.

This structural tension mirrors earlier challenges faced with routine immunizations under UIP, where vaccine wastage has hovered around 25% in states with poor warehousing and cold-chain infrastructure. The HPV vaccine, which requires two spaced doses for complete coverage, is especially vulnerable to such logistical inefficiencies. States like Kerala and Tamil Nadu may fare better given their superior public health systems, but national averages will hinge on whether the weaker links in the system are adequately supported.

International Perspective: The Rwanda Success Story

As India grapples with these challenges, Rwanda offers a striking counterpoint. This small East African nation became the first African country to include HPV vaccination as part of its national immunization programme in 2011. Rwanda partnered with Merck, the pharmaceutical giant, and utilized a school-based delivery model covering girls aged 12. By 2021, over 93% of eligible Rwandan girls had been fully vaccinated, drastically reducing cervical cancer prevalence by at least 50% within five years.

The key to Rwanda’s success was mobilizing a broad coalition of stakeholders—teachers, community leaders, and religious institutions—to proactively address cultural and parental resistance. Contrast this with India's unevenly committed local leadership and often inadequate training for ground-level public healthcare workers. While the Serum Institute’s pricing innovation democratizes access, the Rwandan example underlines that vaccines alone cannot combat systemic scepticism or overcome infrastructural voids.

Bridging the Gaps: Metrics and Accountability

What would success look like for India’s HPV vaccine drive? At its core, this program must achieve three outcomes:

• A double-digit reduction in cervical cancer morbidity and mortality rates by 2030.
• Coverage of at least 90% of adolescent girls, including out-of-school demographics, by leveraging India’s vast anganwadi network.
• Minimized vaccine wastage, below 10%, by addressing health worker shortages and revamping cold-chain infrastructure.

However, success also depends on accountability mechanisms. The UIP, over the years, has faced criticism for opaque performance evaluations. Annual reports survey immunization metrics broadly, but HPV-specific data aggregation will need sharper focus. Monthly and quarterly targets should be publicly documented and audited—ideally complemented by partnerships with independent civil society watchdogs to assess ground realities.

The acid test lies in sustainability. Will this programme retain budgetary and political prioritization as public attention wanes? Too many health initiatives in India suffer from short-lived momentum—high-profile launches followed by slow rollouts and eventual neglect. The HPV vaccine drive risks following this arc if lessons from previous immunization programmes are ignored. Policymakers must step beyond announcement-driven politics towards institutionalized mechanisms capable of enduring long-term scrutiny.

Practice Questions for UPSC

Prelims Practice Questions

Frequently Asked Questions